非小细胞肺癌组织COX-2和p53表达及其临床意义的研究  

Expressions of COX-2 and p53 in non-small cell lung cancer by tissue microarray analysis

作　　者：宋娜[1] 金波[1] 刘云鹏[1] 于萍[1] 

机构地区：[1]中国医科大学附属第一医院肿瘤内科,辽宁沈阳110001

出　　处：《中华肿瘤防治杂志》2008年第16期1247-1250,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：辽宁省科技攻关计划(2004225004-11;2005225013-7)

摘　　要：目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中环氧化酶-2(cyclooxygenase-2,COX-2)和p53表达与病理特征和预后之间的关系。方法:将88例NSCLC及10例正常肺组织标本制作成组织芯片,应用免疫组织化学SP法检测COX-2和p53的表达,并与临床病理特征及长期生存率进行比较分析。结果:COX-2胞质和p53胞核阳性表达率分别为71.6%(63/88)和35.2%(31/88),而正常肺组织均为阴性。NSCLC患者的COX-2(χ2=20.045,P=0.000)和p53表达(χ2=5.153,P=0.028)均明显高于正常肺组织。COX-2和p53表达无相关性,P=0.694。COX-2在女性(χ2=8.213,P=0.005)、不吸烟(χ2=5.086,P=0.027)、腺癌(χ2=12.137,P=0.001)、淋巴结转移阳性(χ2=9.475,P=0.003)和Ⅲ期(χ2=6.761,P=0.017)患者中表达升高,与年龄、分化程度和肿瘤大小无关。COX-2表达者生存时间短,χ2=5.986,P=0.014。p53表达与年龄等临床参数和生存期均无关,P均>0.05。多因素分析显示,COX-2和p53不是影响NSCLC预后的独立危险因素。结论:COX-2阳性表达者预后差,可能在预后判定中有重要作用。OBJECTIVE：To explore the relationship between the expressions of COX-2 and p53 and clinicopathologic parameters and overall survival in patients with non-small cell lung cancer （NSCLC）. METHODS： Expressions of COX-2 and p53 were accessed by the immunohistochemical staining on tissue microarray sections made of 88 cases of NSCLC and 10 cases of normal lung samples, and the results were compared with relevant clinical and pathologic data. RESULTS： The cytoplasmic expression of COX-2 was detected in 71.6%（63/88）, and nuclear expression of p53 was detected in 35.2%（31/88）. Neither COX-2 nor p53 expression were observed in normal lung tissues. The expressions of COX-2 （χ^2=20.045,P=0.000） and p53 （χ^2=5.153, P=0.028） in NSCLC were significant higher than those in the normal lung tissues. There was no correlation between the expressions of COX-2 and p53,P=0.694. The positive expression of COX-2 was significantly higher in the groups with female （χ^2=8.213,P=0.005）, non-smokers （χ^2=5.086,P=0.027）, adenocarcinoma （χ^2=12.137,P=0.001）, lymph node metastasis （χ^2=9.475,P=0.003） and stage Ⅲ （χ^2=6.761,P=0.017）, respectively. The patients with positive expression of COX-2 had worse overall survival,χ^2=5.986, P=0.014. The expression of p53 had no relationship with clinicopathologic parameters or survival, P〉0.05. Multivariate analysis using Cox regression modal showed that neither COX-2 nor p53 was the important independent prognostic factor for survival. CONCLUSION： Aberrant expression of COX-2 is related to shorter overall survival and it may be useful as an indicator for prognosis in NSCLC.

关 键 词：肺肿瘤/病理学 蛋白质 p53 前列腺素内过氧化物合酶 预后 芯片分析技术 

分 类 号：R734.2[医药卫生—肿瘤]